Startups
Turing Pharmaceuticals raised the price of Daraprim from $13.50 to $750 per pill in 2015. Complete factual record of the controversy, criminal case, and antitrust settlement.
Overview
Location
United States, New York
Employees
51-200
Total raised
$90M
Founded date
2014
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 12
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 18, 2015 | Martin Shkreli out as Turing CEO. Ron Tilles named interim replacement | Martin Shkreli, the pharmaceutical executive who became the public face of greed in the industry and who was arrested this week on securities fraud charges, has been replaced. His company, Turing Pharmaceuticals, announced Friday that Shkre... |
| Dec 3, 2015 | Now Martin Shkreli Wishes He Could Have Raised the Price of His $750 Pill Even Higher | On Thursday, Martin Shkreli, the CEO of Turing Pharmaceuticals, and some kind of human sponge designed to absorb all of the world's hatred, announced at an event held by Forbes that he thinks he should have raised the price of Daraprim high... |
| Nov 25, 2015 | Turing Refuses To Lower Cost Of Daraprim, Hides News Ahead Of Thanksgiving Holiday | When last we checked in with Martin Shkreli — founder of Turing Pharmaceuticals and the personification of everything that’s wrong with the pharmaceutical industry and mankind — he was feebly defending his company’s decision to jack up the ... |
| Oct 23, 2015 | Convenient timing, Shkreli: Turing’s epilepsy drug gets fast-tracked by FDA | “With our first investigational candidate moving into the clinic, this is a very exciting moment at Turing Pharmaceuticals,” CEO Martin Shkreli said in a statement. “We are pleased that FDA has granted Fast Track status for TUR-004 providin... |
| Oct 23, 2015 | A $750 Pill And Its Brash Owner Get Competition — And It Costs $1 | Turing Pharmaceuticals, a months-old biotech startup that is largely financed by its 32-year-old founder and CEO Martin Shkreli, sparked widespread outrage last month. The reason: shortly after paying $55 million for a 62-year-old drug call... |
| Sep 21, 2015 | A $750 Pill And A Founder Who Doesn’t Know When To Stop Tweeting | A Twitter account in the hands of a hothead startup founder can be a dangerous thing. The New York Times ran a piece Sunday looking into why a 62-year-old pill saw its price skyrocket from $13.50 to nearly $750 after it was acquired by Turi... |
| Aug 31, 2015 | Turing Pharmaceuticals Announces $90 Million Series A Financing | |
| Aug 10, 2015 | Daily funding roundup - August 10, 2015 | Editas Medicine Inc secured $120M; Turing Pharmaceuticals bagged $90M; Vainglory raised $26M Editas Medicine Inc. raised $120 million from investors to support development of a technology that can precisely edit DNA and potentially treat fa... |
| Aug 10, 2015 | Turing Pharmaceuticals Completes $90M Series A Financing | Turing Pharmaceuticals AG, a New York City and Zug, Switzerland-based biopharmaceutical company focused on discovering and developing treatments for serious and life-threatening diseases, completed a $90m Series A financing. The round was l... |
Show more